Dr. E Mittendorf

BWH/DFCI #breastcancer surgeon. Immunotherapist. Tweets are my own. #BCSM #immunotherapy

[Dr. E Mittendorf @EMittendorfMD]

Cutting edge scientific innovation and real world clinical practice to include highlighting unique challenges in specific global regions. Was a fantastic meeting; highly engaged attendees; great energy. #ascobt26

[Julie Gralow @jrgralow]

Thanks to all who attended and contributed to @ASCO Breakthrough #ascobt26 in Singapore this past week. Looking forward to seeing you here again next year - June 24-27, 2027. @CliffordHudis @ASCOPres

[Julie Gralow @jrgralow]

#ASCO26 Trainee and Early Career Lounge Offers Terrific Networking Opportunities - check it out! https://t.co/JmhxlTFfd9

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Join us for the #DuctalCarcinomaInSitu Program 4th annual virtual patient forum.

This free virtual event features informational presentations about #DCIS for patients, families, loved ones, and health care professionals. All are welcome!

🗓️ May 16, 2026 | 9 a.m. - Noon ET

Featured presentations include:
• Menopausal hormonal therapy
• GLP-1 inhibitors and breast cancer risk
• Innovation in #BreastCancer risk assessment
• Nutrition recommendations
• Movement class
• Cooking demonstration
Each presentation will include a Q&A session. All sessions will be recorded for later viewing.

For more information and to register, visit: https://t.co/ljztk8kPqU

[ASCO @ASCO]

Recommend a colleague by June 5, 2026, for the upcoming ASCO Election.

Learn more and submit your recommendations: https://t.co/NjJ1k40Bey

[Julie Gralow @jrgralow]

#ASCO26 is rapidly approaching - followed shortly afterwards by #ASCOBT26 in Singapore! Looking forward to science and networking with @ASCO and the global community. Register by May 20 to secure the early registration discount! Join me there: https://t.co/t9MnX6ZeFn #OncTwitter

[ASCO @ASCO]

Experience world-class science at an ASCO meeting in Singapore this June or online. Co-hosted with @SSO_Singapore, connect w/ peers & hear about the latest oncology advances. #ASCOBT26 is The Place to Be. Early registration ends May 20; reserve your spot: https://t.co/pbB58Yq2EP

[ASCO @ASCO]

With three more ASCO meetings this year, there are still plenty of opportunities to connect with peers, discover groundbreaking cancer research, & gain clinical insights. Don't miss out on our meetings—the ultimate Place to Be.

Where will we see you this year?

[Dr. E Mittendorf @EMittendorfMD]

2 weeks to go until our 4th annual DCIS patient forum. Looking forward to great talks on menopausal hormonal therapy, impact of GLP1 inhibitors on breast cancer risk, mammography AI-based risk assessment as well as diet and exercise demonstrations.

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

📢 Join us for the #DCIS Program 4th annual virtual patient forum. This free virtual event features informational presentations about DCIS for patients, families, loved ones, and health care professionals.
All are welcome!

🗓️ May 16, 2026 | 9 a.m. - Noon ET

Featured presentations include:
• Menopausal hormonal therapy
• GLP-1 inhibitors and breast cancer risk
• Innovation in breast cancer risk assessment
• Nutrition recommendations
• Movement class
• Cooking demonstration
Each presentation will include a Q&A session. All sessions will be recorded for later viewing.

For more information and to register, visit: https://t.co/A5ADR0rGeM

[Toni Choueiri, MD @DrChoueiri]

At #ASCOAdvocacySummit2026, I joined colleagues from our state of Massachusetts and across the country in meetings on Capitol Hill to speak up for patients with cancer and the care they need.

We focused on three priorities:

-Robust federal support for cancer research
Continued investment in the National Cancer Institute (NCI) and The National Institutes of Health is essential to discovery, innovation, and better outcomes for patients. That way, we also keep talents and innovation in the US.

-Fix Prior authorizations: delays can stand between patients and timely treatment. Care decisions should be driven by medical judgment and patient need—not administrative delays.

-Permanent Medicare #Telehealth access
Telehealth has expanded access in meaningful ways for many of our patients. Preserving that access matters.

Science is moving forward. Policy must keep pace so that advances in cancer care reach every patient.

Thank you @RepStephenLynch (MA, 8th D) for being there in person and meeting with us.

@ASCO @DanaFarber @EMittendorfMD @CliffordHudis

[ASCO @ASCO]

“This is the most important thing you’ll do in D.C. and you have to do it with regularity and purpose… There is no one doing more important work than you.” Thanks, @apalmerdc & @JakeSherman for your keynote & insights.

#ASCOAdvocacySummit #CancerCare

[ASCO @ASCO]

Abstract titles for #ASCO26 are now available! Get a first look at the science that will be presented and be a part of the conversation.

Browse the titles and start planning your experience: https://t.co/FU8HT8vCZ1

If you haven’t yet registered, early reg ends tomorrow!

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

📢 Join us for the #DuctalCarcinomaInSitu Program 4th annual virtual patient forum. This free virtual event features informational presentations about #DCIS for patients, families, loved ones, and health care professionals. All are welcome!

🗓️ May 16, 2026 | 9 a.m. - Noon ET

Featured presentations include:
• Menopausal hormonal therapy
• GLP-1 inhibitors and breast cancer risk
• Innovation in #BreastCancer risk assessment
• Nutrition recommendations
• Movement class
• Cooking demonstration

Each presentation will include a Q&A session. All sessions will be recorded for later viewing.

For more information and to register, visit: https://t.co/A5ADR0rGeM

[ASCO @ASCO]

Thanks @RepBuddyCarter & @HouseCommerce for speaking up for people with cancer and your efforts to #FixPriorAuth.
#PassTheSeniorsAct #ASCOAdvocacy

[Sarah Premji, MD @SPremji7866]

Top oncology reads as we head into 2026 - curated by @ASCOTECAG in collaboration with well established leaders in each disease area! Love being part of this strong group of passionate oncologists! 2026 here we come! @ASCO @SCRIOncology @SarahCannonDocs

[Dr. E Mittendorf @EMittendorfMD]

It takes a team - new @ASCO guidelines on managing patients diagnosed with cancer while pregnant

[ASCO @ASCO]

“Multidisciplinary care for a patient who's diagnosed with cancer while pregnant is essential.” In this “Science in Seconds,” @AnnPartridgeMD & Dr. Alison Loren discuss our first guideline on cancer during pregnancy.

Read the guideline in @JCO_ASCO: https://t.co/7SuqJL3qTy

[Dr. E Mittendorf @EMittendorfMD]

Congrats @VKaklamani to you and your entire team; another great @SABCSSanAntonio

[VIRGINIA KAKLAMANI @VKaklamani]

Another #sabcs25 in the books. Such a team effort from all our committees staff volunteers advocates. Thank you to my codirector @CarlosArteagaMD and the Sabcs program coordinator @KateIdaLathrop. See you all next year. @SABCSSanAntonio @mayscancer @AACR

[Dr. E Mittendorf @EMittendorfMD]

Congratulations to friend and colleague @stolaney1 for her well deserved recognition with the AACR outstanding Investigator Award for her work to advance our efforts personalizing therapy for breast cancer patients.

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Sara Tolaney, MD, MPH (@stolaney1) delivering the #SABCS25 Outstanding Investigator Award for Breast Cancer Research. Dr. Tolaney's leadership in establishing biomarker-driven personalized therapy approaches for cancer, including the development of CDK4/6 inhibitors, has significantly advanced care in both metastatic and adjuvant settings, shaping the future of precision oncology for patients with #BreastCancer. @AACR @BCRFcure

[Sara Tolaney @stolaney1]

A true privilege to be part of such an extraordinary group!

@DFCI_BreastOnc #SABCS25

[Dr. E Mittendorf @EMittendorfMD]

Honored to represent @ASCO at #JSCO2025. A true highlight was meeting with the ASCO/JSCO fellows whose talent and passion was invigorating to witness. Also, the excellent joint sessions on ctDNA, ADCs, & #ASCO25 data with regional context. Thank you to our gracious JSCO hosts.

[Dr. E Mittendorf @EMittendorfMD]

Honored to help kick off Japan Society of Clinical Oncology meeting with outstanding session reviewing important trial data from #ASCO25 annual meeting and implications for patients in the Asia Pacific region. Thx to our speakers for lending their time and expertise @ASCO